Division

FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure

Retrieved on: 
Friday, February 16, 2024

Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

Key Points: 
  • Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.
  • "While it will not eliminate food allergies or allow patients to consume food allergens freely, its repeated use will help reduce the health impact if accidental exposure occurs."
  • Current treatment requires strict avoidance of the food(s) the patient is allergic to, and prompt administration of epinephrine to treat anaphylaxis should accidental exposures occur.
  • Xolair is the first FDA-approved medication to reduce allergic reactions to more than one type of food after accidental exposure.

AI (and other) Companies: Quietly Changing Your Terms of Service Could Be Unfair or Deceptive

Retrieved on: 
Friday, February 16, 2024

And there is perhaps no data refinery as large-capacity and as data-hungry as AI.

Key Points: 
  • And there is perhaps no data refinery as large-capacity and as data-hungry as AI.
  • But many of these companies also have privacy and data security policies in place to protect users’ information.
  • And to avoid backlash from users who are concerned about their privacy, companies may try to make these changes surreptitiously.
  • The company did that without notifying consumers who had previously shared personal data or obtaining their consent, said the FTC.

Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Retrieved on: 
Thursday, February 15, 2024

SAN DIEGO, Feb. 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting multiple posters from all three clinical development programs in rare muscle diseases, including new AOC 1001 long-term efficacy and safety data from the MARINA open-label extension (MARINA-OLE™) trial in people living with myotonic dystrophy type 1 (DM1) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida.

Key Points: 
  • ET for a live video webcast event, which will be available on the company's website.
  • The company is hosting Volume 8 of its investor and analyst event series on March 4, 2024, beginning at 8:00 a.m.
  • ET to discuss new AOC 1001 long-term efficacy and safety data from the MARINA-OLE™ trial in people living with DM1.
  • A replay of the webcast will be archived on Avidity's website following the event.

Reverse Hip Replacement System Unveiled at Global Orthopedic Surgery Meeting

Retrieved on: 
Thursday, February 15, 2024

SAN FRANCISCO, Feb. 15, 2024 /PRNewswire/ -- Hip Innovation Technology, LLC (HIT), a medical device company developing innovative orthopedic device solutions to advance the quality of life and quality of care for patients, today announced that its flagship product, the Reverse Hip Replacement System (Reverse HRS) was showcased at the 2024 American Academy of Orthopaedic Surgeons (AAOS) annual meeting, taking place in San Francisco, CA from February 12 -16, 2024.

Key Points: 
  • "We are extremely excited that the Reverse HRS was featured at AAOS in the OrthoDome with a video of an actual hip replacement surgery narrated by Dr. Adolph Lombardi," said George Diamantoni, Hip Innovation Technology's Co-Founder and Chief Executive Officer.
  • The presentation featured high resolution video of Dr. Lombardi conducting a hip replacement with the new Reverse HRS.
  • The Bone & Joint Open journal, recently published the article, "Radiostereometric analysis and clinical outcomes of a novel reverse total hip system at two years."
  • Hip replacement surgery, or total hip arthroplasty, is one of the most common joint replacement procedures done in the United States.

PredxBio Appoints Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors

Retrieved on: 
Thursday, February 15, 2024

PITTSBURGH, Feb. 15, 2024 /PRNewswire-PRWeb/ -- PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.

Key Points: 
  • PITTSBURGH, Feb. 15, 2024 /PRNewswire-PRWeb/ -- PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.
  • Dusty Majumdar, PhD, CEO of PredxBio
    "We are thrilled and privileged to announce the appointment of Dr. Marks as the Chairman of PredxBio's Board of Directors," expressed Dusty Majumdar, PhD, CEO of PredxBio.
  • "I am honored to serve as Chairman of the Board of Directors at PredxBio," commented Dr. Marks.
  • Supported by over 20 peer-reviewed publications, 4000+ citations, and numerous patents, PredxBio contributes significantly to improving cancer care.

New Chair and Executive Committee Members Appointed of Lymphoma Research Foundation Mantle Cell Lymphoma Consortium

Retrieved on: 
Thursday, February 15, 2024

NEW YORK, Feb. 15, 2024 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) – the nation's largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – is pleased to announce Tycel Phillips, MD of City of Hope and Kami Maddocks, MD of Ohio State University to the Executive Committee members and Peter Martin, MD of Weill Cornell Medicine as Chair of its Mantle Cell Lymphoma Consortium (MCLC) Executive Committee.

Key Points: 
  • "LRF's Mantle Cell Lymphoma Consortium provides a unique forum for the world's leading MCL researchers to share scientific and clinical findings, exchange ideas, and plan new collaborations," said Meghan Gutierrez, CEO of the Lymphoma Research Foundation
    The Mantle Cell Lymphoma Consortium Executive Committee helps to guide the MCLC by identifying gaps in research and patient care for this historically understudied patient population.
  • Since its inception the Mantle Cell Lymphoma Consortium brings together leading international experts to discuss the latest research findings, foster collaboration within the mantel cell lymphoma (MCL) research community, create new directions for research, and ultimately improve diagnosis and treatment for this disease.
  • "The Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium provides a unique forum for the world's leading MCL researchers to share scientific and clinical findings, exchange ideas, and plan new collaborations," said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation.
  • "I'm honored to lead this vital consortium dedicated to improving outcomes for all those impacted by mantle cell lymphoma," said Dr. Martin.

Brooke Eby, ALS Patient and Advocate, to deliver Keynote Address at 2024 MDA Clinical & Scientific Conference

Retrieved on: 
Thursday, February 15, 2024

New York, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific Conference (being held in Orlando, FL March 3-6), where she will address the world’s leaders in neuromuscular disease research and care.

Key Points: 
  • New York, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific Conference (being held in Orlando, FL March 3-6), where she will address the world’s leaders in neuromuscular disease research and care.
  • As the largest US gathering focused solely on neuromuscular diseases including ALS, the 2024 MDA Clinical & Scientific Conference promises to delve into the latest research advancements and clinical achievements in the field.
  • "We are honored to have Brooke Eby grace our conference to share her story and insights as a patient and as a patient advocate," remarked Sharon Hesterlee, Ph.D., Chief Research Officer, MDA.
  • Members of the neuromuscular community who are registered with MDA are welcome to participate in the virtual conference at no-cost.

Simulations Plus Extends Collaboration with Major Toxicology Research Agency

Retrieved on: 
Thursday, February 15, 2024

“At NIEHS, we seek to expand scientific knowledge and approach methods linking the environment and human health.

Key Points: 
  • “At NIEHS, we seek to expand scientific knowledge and approach methods linking the environment and human health.
  • “Importantly, these tools are being investigated for their potential to address a critical gap in toxicology research for understanding and modeling human bioactivation of environmental chemicals through xenobiotic metabolism,” Ferguson added.
  • Principal Scientist in the Cheminformatics Solutions team at Simulations Plus.
  • It is the leading physiologically based pharmacokinetic/physiologically based biopharmaceutics modeling (PBPK/PBBM) platform, built and refined over 25 years on the most up-to-date scientific research.

City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia and HIV Published in The New England Journal of Medicine (NEJM)

Retrieved on: 
Wednesday, February 14, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240214747351/en/
    "City of Hope Patient" Paul Edmonds with City of Hope doctors, Jana K. Dickter, M.D., and Monzr Al Malki, M.D.
  • Edmonds is also the person who had HIV the longest — for over 31 years — among these five patients.
  • Known as the “City of Hope patient” among these five patients, Edmonds received a transplant at City of Hope on Feb. 6, 2019, and is now considered to be cured of leukemia.
  • City of Hope has exceptional transplant outcomes year after year, according to the Center for International Blood & Marrow Transplant Research.

The SoCal Laborers Training School Graduates More Than 750 Highly-Skilled Construction Professionals To Journeyperson Status

Retrieved on: 
Wednesday, February 14, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240214780580/en/
    Business Manager of the Southern California District Council of Laborers Jon P. Preciado addresses the 2023 graduates and their families.
  • (Photo: Business Wire)
    “The graduates’ years of grit, sacrifice and perseverance show the commitment that our members and this union have for the construction industry.
  • Presently, the Laborers’ Training School has nearly 2,500 indentured apprentices employed full-time for one of LIUNA’s over 2,000 union-signatory contractors in Southern California.
  • The Laborers’ School operates 12 facilities in Southern California and provided more than 387,361 hours of construction skills training in 2023.